Kişi: DEMİRDÖĞEN, EZGİ
Yükleniyor...
E-posta Adresi
Doğum Tarihi
Durumu
Araştırma Projeleri
Akademik Birimler
Ünvanı
person.page.name
Ad
EZGİ
Soyad
DEMİRDÖĞEN
5 sonuçlar
Arama Sonuçları
Şimdi gösteriliyor 1 - 5 / 5
Yayın Sadece Metadata The age-dependent role of Th22, Tc22, and Tc17 cells in the severity of pneumonia in COVID-19 immunopathogenesis(Wiley, 2021-08) Şimşek, Abdurrahman; Çağan, Eren; Kızmaz, Muhammed Ali; Dombaz, Fatma; Tezcan, Gülçin; Asan, Ali; Demir, H. İbrahim; Bal, S. Haldun; Ermiş, Diğdem Yoyen; Demirdöğen, Ezgi; Heper, Yasemin; Akalın, E. Halis; Oral, Haluk Barbaros; Budak, Ferah; ŞİMŞEK, ABDURRAHMAN; TEZCAN, GÜLÇİN; BAL, SALİH HALDUN; DEMİRDÖĞEN, EZGİ; BUDAK, FERAH; HEPER, YASEMİN; AKALIN, EMİN HALİS; Kızmaz, Muhammed Ali; Dombaz, Fatma; YÖYEN ERMİŞ, DİĞDEM; ORAL, HALUK BARBAROS; Bursa Uludağ Üniversitesi/Tıp Fakültesi; 0000-0001-8850-0269; 0000-0001-5334-7911; 0000-0001-7288-3250; 0000-0002-5956-8755; 0000-0002-7400-9089; 0000-0001-7625-9148; AAG-7381-2021; HKN-2347-2023; DWR-5356-2022; KBR-5535-2024; GYL-2038-2022; AAH-9812-2021; CTY-9474-2022; AAU-8952-2020; IZP-9398-2023; K-7285-2012; AAH-3843-2020Yayın Sadece Metadata Interleukin-21: A potential biomarker for diagnosis and predicting prognosis in covid-19 patients(Tubitak Scientific & Technological Research Council Turkey, 2021-01-01) Acet Ozturk, Nilufer Aylin; ACET ÖZTÜRK, NİLÜFER AYLİN; Ursavas, Ahmet; URSAVAŞ, AHMET; Gorek Dilektasli, Asli; GÖREK DİLEKTAŞLI, ASLI; Demirdogen, Ezgi; DEMİRDÖĞEN, EZGİ; Coskun, Necmiye Funda; COŞKUN, NECMİYE FUNDA; Ediger, Dane; EDİGER, DANE; Uzaslan, Ayse Esra; UZASLAN, AYŞE ESRA; Yoyen-Ermis, Digdem; YÖYEN ERMİŞ, DİĞDEM; Karaca, Mert; KARACA, MERT; Terzi, Orkun Eray; TERZİ, ORKUN ERAY; Bayram, Merve; BAYRAM, MERVE; Omer Topcu, Dilara; ÖMER TOPÇU, DİLARA; Yigitliler, Busra; Yurttas, Ahmet; YURTTAŞ, AHMET; Maharramov, Shahriyar; Yazici, Gamze; YAZICI, GAMZE; Oral, Haluk Barbaros; ORAL, HALUK BARBAROS; Karadag, Mehmet; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-6375-1472; 0000-0001-7099-9647; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0002-2954-4293; 0000-0001-5871-8769; 0000-0003-0463-6818; 0000-0002-9027-1132; AAG-7406-2021; AAD-1271-2019; AAH-3888-2021; K-7285-2012; AAG-8744-2021; AAI-3169-2021; JPK-7012-2023; AAE-9142-2019Background/aim: COVID-19 patients have a wide spectrum of disease severity. Several biomarkers were evaluated as predictors for progression towards severe disease. IL-21 is a member of common gamma-chain cytokine family and creates some specific effects during programming and maintenance of antiviral immunity. We aimed to assess IL-21 as a biomarker for diagnosis and outcome prediction in patients hospitalized with COVID-19. Materials and methods: Patients with a preliminary diagnosis of COVID-19 and pneumonia other than COVID-19 admitted to a tertiary care hospital were included consecutively in this comparative study. Results: The study population consisted of 51 patients with COVID-19 and 11 patients with non-COVID-19 pneumonia. Serum IL-21 concentration was markedly higher, and serum CRP concentration was significantly lower in COVID-19 patients compared to nonCOVID-19 pneumonia patients. Within COVID-19 patients, 10 patients showed radiological and clinical progression. Patients with clinical worsening had lower lymphocyte count and haemoglobin. In addition to that, deteriorating patients had higher urea, LDH levels, and elevated concentration of both IL-6 and IL-21. The cut-off value of 106 ng/L for IL-21 has 80.0% sensitivity, %60.9 specificity for discriminating patients with clinical worsening. Multivariable analysis performed to define risk factors for disease progression identified IL-6 and IL-21 as independent predictors. Odds ratio for serum IL-6 concentrations >_ 3.2 pg/mL was 8.07 (95% CI: 1.3747.50, p = 0.04) and odds ratio for serum IL-21 concentrations >_ 106 ng/L was 6.24 (95% CI: 1.04 - 37.3, p = 0.02). Conclusion: We identified specific differences in serum IL-21 between COVID-19 and non-COVID-19 pneumonia patients. Serum IL-21 measurement has promising predictive value for disease progression in COVID-19 patients. High serum IL-6 and IL-21 levels obtained upon admission are independent risk factors for clinical worsening.Yayın Sadece Metadata Il-21: A potential biomarker for diagnosis and predicting prognosis in covid-19 patients(European Respiratory Society Journals, 2021-09-05) Öztürk, Nilüfer Aylin Acet; Ursavaş, Ahmet; Dilektaşlı, Aslı Görek; Demirdöğen, Ezgi; Coşkun, Funda; Ediger, Dane; Uzaslan, Esra; Yöyen-Ermiş, Diğdem; Karaca, Mert; Terzi, Orkun; Bayram, Merve; Ömer, Dilara; Yiğitliler, Büşra; Yurttaş, Ahmet; Maharramov, Shahriyar; Çelik, Gamze; Oral, Barbaros; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; URSAVAŞ, AHMET; GÖREK DİLEKTAŞLI, ASLI; DEMİRDÖĞEN, EZGİ; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; UZASLAN, AYŞE ESRA; YÖYEN ERMİŞ, DİĞDEM; KARACA, MERT; TERZİ, ORKUN ERAY; BAYRAM, MERVE; ÖMER TOPÇU, DİLARA; YURTTAŞ, AHMET; ORAL, HALUK BARBAROS; KARADAĞ, MEHMET; MAHARRAMOV, SHAHRİYAR; YAZICI, GAMZE; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-6375-1472; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0002-2954-4293; 0000-0001-5871-8769; 0000-0002-9027-1132; AAG-8744-2021; JPK-7012-2023; AAH-3888-2021; AAE-9142-2019; AAI-3169-2021; AAD-1271-2019Yayın Sadece Metadata Impact of covid-19 pneumonia on pulmonary function, functional exercise capacity and quality of life(European Respiratory Soc Journals, 2021-09-05) Dilektasli, Asli Gorek; GÖREK DİLEKTAŞLI, ASLI; Ozturk, Nilufer; ACET ÖZTÜRK, NİLÜFER AYLİN; Odabas, Ayten; Demirdogen, Ezgi; DEMİRDÖĞEN, EZGİ; Ursavas, Ahmet; URSAVAŞ, AHMET; Coskun, Funda; COŞKUN, NECMİYE FUNDA; Guclu, Ozge Aydin; AYDIN GÜÇLÜ, ÖZGE; Ediger, Dane; EDİGER, DANE; Uzaslan, Esra; UZASLAN, AYŞE ESRA; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0003-1005-3205; 0000-0002-2954-4293; AAI-3169-2021; AAE-9142-2019; JPK-7012-2023; AAD-1271-2019Yayın Sadece Metadata Is serum iron responsive protein-2 level associated with pulmonary functions and frequent exacerbator phenotype in copd?(Turkish Assoc Tuberculosis & Thorax, 2020-01-01) Öztürk, Nilufer Aylin Acet; ACET ÖZTÜRK, NİLÜFER AYLİN; Dilektaşlı, Aslı Görek; GÖREK DİLEKTAŞLI, ASLI; Demirdoğen, Ezgi; DEMİRDÖĞEN, EZGİ; Coşkun, Funda; COŞKUN, NECMİYE FUNDA; Ursavas, Ahmet; URSAVAŞ, AHMET; Karadağ, Mehmet; KARADAĞ, MEHMET; Uzaslan, Esra Kunt; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; 0000-0002-6375-1472; 0000-0001-7099-9647; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0002-9027-1132; JPK-7012-2023; Z-1424-2019; AAI-3169-2021; AAD-1271-2019; AAH-9812-2021; AAI-1004-2021; AAG-8744-2021Introduction: Chronic Obstructive Pulmonary Disease (COPD) exacerbations contribute to the overall severity in individual patients because they are associated with airway inflammation, pulmonary function loss, decreased quality of life and increased mortality. Although, identifying frequent exacerbator patients is important due to severe outcomes associated with frequent exacerbator phenotype in COPD patients there is no single biomarker which can differentiate this phenotype. Iron responding protein-2 (IRP2) is the protein product of IREB2 gene, which is a COPD susceptibility gene that regulates cellular iron homeostasis and has a key role in hypoxic conditions. Previous research indicates that IREB2 expression in lung tissue is associated with spirometric measurements and emphysema in COPD. In this study, our aim was to investigate whether serum IRP2 levels were associated with frequent exacerbator phenotype, to evaluate whether IRP2 levels in serum are associated with pulmonary functions and selected systemic inflammation biomarkers.Materials and Methods: Designed as a single tertiary care center based, cross-sectional study, included high risk (GOLD C, D) COPD patients who admitted to outpatient clinic consecutively between December 2015 and July 2016.Results: The study included 80 COPD patients. Serum IRP2 levels were negatively correlated with FEV ml (r= -0.25, p= 0.02) and body weight (r= -0.35, p= 0.002) but not with markers of systemic inflammation. COPD patients with at least one exacerbation history in the last year tended to have higher 1RP2 levels than patients without any exacerbation (12.3 (IQR 25-75: 10.417.1) vs 10.5 (1QR 25-75: 8.8-18.5), p= 0.061.Conclusion: Serum IRP2 level is significantly correlated with FEV1 mL but not with FEV1 predicted and cannot be used to differentiate frequent exacer bator patients. Although IREB2 gene expressions in lung tissue and bronchoalveolar lavage results have significant associations with emphysema and FEV1/FVC, FEV1 %predicted in COPD patients, our results suggests serum IRP2 level is not as promising.